Home   Business   Article

Subscribe Now

STORM Therapeutics appoints Dr John Haurum to board

STORM Therapeutics has appointed the former CEO of F-star, Dr John Haurum, to its board of directors.

John Haurum, CEO of F-star. (13194708)
John Haurum, CEO of F-star. (13194708)

The Cambridge drug discovery company is focused on the discovery of small molecule therapies modulating RNA epigenetics

Dr Haurum, who joins as an independent non-executive director, led Babraham-based clinical-stage biopharmaceutical company F-star as it developed bispecific antibodies and secured major collaborations with AbbVie, Merck KGaA, Denali and Boehringer Ingelheim.

Dr Keith Blundy, CEO of STORM Therapeutics, also based at Babraham, said: “STORM is progressing fast in its preclinical work with our multiple programmes to showcase the capabilities of our novel platform.

“On behalf of the board of directors, I would like to welcome John to STORM where his experience of developing both oncology platforms and clinical stage companies will be invaluable.”

Dr Haurum, who held previous posts at ImClone Systems and Symphogen, said: “STORM is a pioneer in RNA epigenetics and the company is at a very exciting stage of progression and growth, having raised significant investor funding to advance the first compounds in preclinical development.

“I look forward to working with the board and the management team to create first-in-class drugs and improving the lives of cancer patients.”

Dr Haurum is also executive chairman of the board at Synklino, chairman of the Board of Agomab and is on the board of NeoPhore and Synact Pharma ApS.

STORM, which won Biotech Start-up of the Year at the 2017 Cambridge Independent Science and Technology Awards, will host its inaugural RNA Epigenetics in Human Disease Conference from September 17-20 at St Catherine's College, Cambridge. Register at stormtxconference2019.com.

Read more

How F-star is supercharging the immune system in fight against cancer

How F-star could earn milestone payments of up to $447m after Denali Therapeutics deal

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More